# Ketamine for Treatment-Resistant Bipolar Disorder

> **NCT05004896** · PHASE2 · COMPLETED · sponsor: **Joshua Rosenblat** · enrollment: 71 (actual)

## Conditions studied

- Bipolar Disorder
- Bipolar Depression
- Bipolar I Disorder
- Bipolar II Disorder

## Interventions

- **DRUG:** Ketamine Hydrochloride
- **DRUG:** Midazolam Hydrochloride

## Key facts

- **NCT ID:** NCT05004896
- **Lead sponsor:** Joshua Rosenblat
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-04
- **Primary completion:** 2025-11-14
- **Final completion:** 2025-11-14
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05004896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05004896, "Ketamine for Treatment-Resistant Bipolar Disorder". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05004896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*